Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 31.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,087 shares of the company's stock after selling 17,750 shares during the period. Wedge Capital Management L L P NC owned about 0.08% of Prestige Consumer Healthcare worth $3,360,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Kestra Investment Management LLC bought a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth $27,000. CIBC Private Wealth Group LLC raised its position in shares of Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after acquiring an additional 152 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth $40,000. McIlrath & Eck LLC raised its position in shares of Prestige Consumer Healthcare by 19.1% in the 4th quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after acquiring an additional 154 shares in the last quarter. Finally, Johnson Financial Group Inc. bought a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth $93,000. 99.95% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on PBH. Wall Street Zen raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, May 17th. Oppenheimer upped their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a research report on Thursday, February 13th. Finally, Royal Bank of Canada raised Prestige Consumer Healthcare to a "hold" rating in a research report on Thursday, May 8th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $93.33.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock traded down $1.30 during trading hours on Friday, hitting $83.84. 222,224 shares of the stock traded hands, compared to its average volume of 299,192. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The firm's 50 day moving average price is $83.68 and its 200-day moving average price is $82.56. The stock has a market capitalization of $4.14 billion, a price-to-earnings ratio of 19.63, a P/E/G ratio of 2.69 and a beta of 0.45. Prestige Consumer Healthcare Inc. has a 1 year low of $63.79 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.02. The business had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The company's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.02 EPS. As a group, equities analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.